FDA Approves AstraZeneca's FluMist Nasal Spray, First Self-Administered Flu Vaccine

Sep 20, 2024, 08:06 PM

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self- or caregiver-administration. This marks the first time a flu vaccine can be administered at home without the need for a healthcare provider, making it the first of its kind. The vaccine, which is licensed for individuals aged 2 to 49, aims to increase accessibility and reduce barriers to flu vaccination. It will be available through third-party pharmacies, where users will complete a screening and eligibility assessment. The approval aligns with the FDA's broader efforts to expand consumer access to medications and reduce healthcare costs.